Turn Therapeutics Inc. (TTRX) Cash Flow Statement
Turn Therapeutics Inc. (TTRX) generated -$4.3M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$4.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TTRXTurn Therapeutics Inc.Follow TTRX — free
—
Price chart with a free account
- Market cap
- 306.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 18 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -1.4 | -2.6 | -4.3 | |
| Capital expenditure | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -1.4 | -2.6 | -4.3 | |
| Stock-based compensation | 0.4 | 0.4 | — |
USD millions · SEC XBRL
Turn Therapeutics Inc. — questions
- What is Turn Therapeutics Inc.'s operating cash flow?
- -$4.3M over the twelve months to 2026-06-30.
- How much does Turn Therapeutics Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Turn Therapeutics Inc.'s free cash flow?
- -$4.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Turn Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.